Quantum BioPharma Ltd. (QNTM) 10-Year Financial Performance & Capital Metrics

QNTM • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

AboutQuantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.Show more

Revenue $0
EBITDA -$16M +26.5%
Net Income -$14M +20.7%
EPS (Diluted) -12.49 +57.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -121.65% -47.6%
ROIC -153.57% -5.7%
Debt/Equity 0.08 +200.7%
Interest Coverage -339.16 +99.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 86.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-180.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM-20.25%

ROCE

10Y Avg-84.15%

5Y Avg-94.21%

3Y Avg-104.09%

Latest-138.22%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.49B	135.33	41.13	24.81%	15.95%	14.25%	4.13%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.97B	51.80	39.24	8.94%	-2.8%	-1.82%	5.76%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	26.94M	7.01	-0.56			-379.78%		0.08
AYTUAytu BioPharma, Inc.	28.02M	2.75	-1.27	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	429.45M	3.52	-6.90	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.50	-42.16	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	17.39B	35.17	-4042.53			-67.02%		0.01

Profit & Loss

	Aug 2015	Aug 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	20.63K	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	2.04M	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	20.63K	0	-1.84M	0	0	0	0	0
Gross Margin %	-	-	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-1%	-	1%	-	-	-	-
Operating Expenses+	32.8K	29.63K	2.82M	18.62M	20.44M	30.69M	33.74M	27.43M	23.79M	16.14M
OpEx % of Revenue	-	-	136.86%	-	-	-	-	-	-	-
Selling, General & Admin	32.8K	29.63K	2.82M	17.49M	20.49M	18.11M	23.37M	15.98M	13.2M	9.31M
SG&A % of Revenue	-	-	136.86%	-	-	-	-	-	-	-
Research & Development	0	0	0	0	0	7.83M	6.33M	6.91M	3.86M	6.08M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	1.13M	-45.53K	4.75M	4.05M	4.54M	6.73M	742.8K
Operating Income+	0	0	-2.8M	0	-22.48M	-30.69M	-33.74M	-27.43M	-23.79M	-16.14M
Operating Margin %	-	-	-135.86%	-	-	-	-	-	-	-
Operating Income Growth %	-	-	-	1%	-	-0.37%	-0.1%	0.19%	0.13%	0.32%
EBITDA+	-32.8K	-29.63K	-2.8M	-16.54M	-20.54M	-26.79M	-29.7M	-22.89M	-21.28M	-15.65M
EBITDA Margin %	-	-	-135.86%	-	-	-	-	-	-	-
EBITDA Growth %	-	0.1%	-93.6%	-4.9%	-0.24%	-0.3%	-0.11%	0.23%	0.07%	0.26%
D&A (Non-Cash Add-back)	0	0	0	134.5K	1.94M	3.9M	4.05M	4.54M	2.51M	490.57K
EBIT	-32.8K	-29.63K	-2.8M	-16.67M	-33.93M	-28.22M	-33.87M	-26.65M	-18.23M	-14.87M
Net Interest Income+	0	0	0	0	-155.32K	-231.89K	-68.11K	318.91K	786.06K	525.31K
Interest Income	0	0	0	0	0	3.69K	1.29K	367.74K	786.36K	572.89K
Interest Expense	0	0	0	0	155.32K	235.58K	69.4K	48.82K	299	47.58K
Other Income/Expense	-32.8K	-29.63K	0	-16.67M	-11.6M	2.24M	-194.3K	725.95K	5.56M	1.22M
Pretax Income+	-32.8K	-29.63K	-2.8M	-16.67M	-34.08M	-28.45M	-33.94M	-26.7M	-18.23M	-14.92M
Pretax Margin %	-	-	-135.86%	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.15%	1.12%	1.04%	0.88%	0.98%	0.95%
Net Income+	-32.8K	-29.63K	-2.8M	-16.67M	-39.13M	-31.8M	-35.29M	-23.61M	-17.9M	-14.2M
Net Margin %	-	-	-135.86%	-	-	-	-	-	-	-
Net Income Growth %	-	0.1%	-93.6%	-4.95%	-1.35%	0.19%	-0.11%	0.33%	0.24%	0.21%
Net Income (Continuing)	-32.8K	-29.63K	-2.8M	-16.67M	-34.08M	-28.45M	-33.94M	-26.7M	-18.23M	-14.92M
Discontinued Operations	0	0	0	0	0	-3.35M	-1.35M	3.1M	0	0
Minority Interest	0	0	0	0	0	0	0	0	-327.5K	-1.04M
EPS (Diluted)+	-0.32	-0.29	-27.75	-183.54	-360.45	-171.62	-65.63	-39.62	-29.39	-12.49
EPS Growth %	-	0.09%	-94.69%	-5.61%	-0.96%	0.52%	0.62%	0.4%	0.26%	0.58%
EPS (Basic)	-0.32	-0.29	-27.75	-183.54	-360.45	-171.62	-65.63	-39.62	-29.39	-12.49
Diluted Shares Outstanding	101K	101K	101K	90.85K	108.56K	185.29K	537.62K	595.88K	609.06K	1.14M
Basic Shares Outstanding	101K	101K	101K	90.85K	108.56K	185.29K	537.62K	595.88K	609.06K	1.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.16K	7.14K	4.28M	16.57M	8.56M	26.87M	45.93M	17.85M	11.09M	12.05M
Cash & Short-Term Investments	0	7.14K	3.77M	15.52M	5.97M	17.52M	35.42M	17M	3.51M	7.2M
Cash Only	0	7.14K	3.77M	15.52M	5.97M	17.52M	35.26M	16.98M	2.76M	6M
Short-Term Investments	0	0	0	0	0	0	158.04K	23.19K	756.1K	1.2M
Accounts Receivable	2.16K	0	234.2K	727.58K	1.56M	161.34K	500.96K	374.38K	7.42M	3.81M
Days Sales Outstanding	-	-	4.14K	-	-	-	-	-	-	-
Inventory	0	0	0	0	709.37K	0	0	0	0	117.24K
Days Inventory Outstanding	-	-	-	-	126.96	-	-	-	-	-
Other Current Assets	0	0	0	0	0	8.61M	8.65M	0	0	861.23K
Total Non-Current Assets+	0	0	6.59M	22.18M	34.66M	15.1M	17.03M	20.56M	6.39M	5.07M
Property, Plant & Equipment	0	0	6.59M	8.91M	8.98M	0	168.31K	260.93K	120.42K	130.38K
Fixed Asset Turnover	-	-	0.00x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	16.82M	13.42M	16.2M	12.04M	5.36M	4.93M
Long-Term Investments	0	0	0	13.26M	8.86M	1.68M	660.23K	827.61K	6.05K	2.22K
Other Non-Current Assets	0	0	0	0	0	0	0	7.43M	907.37K	0
Total Assets+	2.16K	7.14K	10.88M	38.75M	43.22M	41.97M	62.96M	38.41M	17.47M	17.12M
Asset Turnover	-	-	0.00x	-	-	-	-	-	-	-
Asset Growth %	-	2.3%	1523.21%	2.56%	0.12%	-0.03%	0.5%	-0.39%	-0.55%	-0.02%
Total Current Liabilities+	60.53K	61.43K	1.01M	1.28M	6.83M	5.58M	8.7M	7.83M	4.57M	6.68M
Accounts Payable	36.75K	28.31K	1.01M	1.28M	3.36M	2.06M	3M	2.76M	3.24M	3.25M
Days Payables Outstanding	-	-	-	-	601.54	-	-	-	-	-
Short-Term Debt	18.04K	0	0	0	1.44M	384.65K	300.55K	300.55K	300.55K	771.14K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	0	0	0	0	1.99M	1.61M	811.43K	243.59K	31.34K	492K
Current Ratio	0.04x	0.12x	4.26x	12.94x	1.25x	4.82x	5.28x	2.28x	2.43x	1.80x
Quick Ratio	0.04x	0.12x	4.26x	12.94x	1.15x	4.82x	5.28x	2.28x	2.43x	1.79x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	110.33K	79.12K	131.04K	38K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	110.33K	79.12K	131.04K	38K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	60.53K	61.43K	1.01M	1.28M	6.94M	5.66M	8.83M	7.87M	4.57M	6.68M
Total Debt+	18.04K	0	0	0	1.59M	510.61K	555.9K	516.42K	339.2K	824.92K
Net Debt	18.04K	-7.14K	-3.77M	-15.52M	-4.38M	-17.01M	-34.7M	-16.46M	-2.42M	-5.17M
Debt / Equity	-	-	-	-	0.04x	0.01x	0.01x	0.02x	0.03x	0.08x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-144.76x	-130.28x	-486.19x	-561.83x	-79563.54x	-339.16x
Total Equity+	-58.37K	-54.3K	9.87M	37.47M	36.28M	36.31M	54.13M	30.54M	12.91M	10.44M
Equity Growth %	-	0.07%	182.81%	2.8%	-0.03%	0%	0.49%	-0.44%	-0.58%	-0.19%
Book Value per Share	-0.58	-0.54	97.74	412.42	334.18	195.95	100.69	51.26	21.20	9.18
Total Shareholders' Equity	-58.37K	-54.3K	9.87M	37.47M	36.28M	36.31M	54.13M	30.54M	13.24M	11.48M
Common Stock	1.06M	1.07M	10.34M	49.87M	73.74M	103.21M	152.32M	143.41M	137.78M	150.47M
Retained Earnings	-1.26M	-1.3M	-3.35M	-19.46M	-59.07M	-90.87M	-126.15M	-144.16M	-157.91M	-172.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	-84.78K	207.8K	239.61K	652.6K	417.34K	50.8K
Minority Interest	0	0	0	0	0	0	0	0	-327.5K	-1.04M

Cash Flow

	Aug 2015	Aug 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-63	-27.24K	-119.18K	-13.58M	-13.71M	-19.13M	-20.75M	-28.33M	-10.83M	-6.88M
Operating CF Margin %	-	-	-5.78%	-	-	-	-	-	-	-
Operating CF Growth %	-	-428.39%	-3.38%	-112.91%	-0.01%	-0.4%	-0.08%	-0.37%	0.62%	0.36%
Net Income	-32.8K	-29.63K	-2.81M	-16.67M	-34.08M	-28.45M	-33.94M	-26.7M	-18.23M	-14.92M
Depreciation & Amortization	0	0	0	134.13K	1.94M	3.9M	4.05M	4.53M	2.51M	490.57K
Stock-Based Compensation	0	0	2.38M	4.73M	12.08M	8.05M	7.44M	1.53M	3.84M	152.21K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	0	0	-1.52M	5.24M	-3.44M	-1.19M	-575.13K	-576.27K	-2.36M
Working Capital Changes	32.74K	2.39K	305.41K	-242.37K	1.1M	807.14K	2.89M	-7.12M	1.64M	9.76M
Change in Receivables	881	2.19K	-217.72K	-487.95K	-387.84K	435.18K	-106.88K	-7.22M	-728.72K	4.52M
Change in Inventory	0	0	0	0	-721.86K	0	0	0	0	-117.24K
Change in Payables	12.62K	-8.87K	790.97K	318.46K	825.12K	0	0	0	0	0
Cash from Investing+	0	0	-6.09M	-7.34M	-230.89K	6.51M	268.96K	12.12M	-269.58K	-1.5M
Capital Expenditures	0	0	-6.09M	-2.96M	-408.89K	0	-500K	-113.96K	0	0
CapEx % of Revenue	-	-	295.02%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-286.06K	36.62K	0	-250K	0	0
Cash from Financing+	0	34.38K	9.95M	32.95M	4.01M	24.17M	38.21M	-2.07M	-3.13M	11.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	34.38K	-1.01M	-81.68K	622.59K	59.55K	0	0	20.25K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-63	-27.24K	-6.21M	-16.54M	-14.01M	-19.13M	-21.25M	-28.7M	-10.83M	-6.88M
FCF Margin %	-	-	-300.8%	-	-	-	-	-	-	-
FCF Growth %	-	-428.39%	-226.82%	-1.66%	0.15%	-0.37%	-0.11%	-0.35%	0.62%	0.36%
FCF per Share	-0.00	-0.27	-61.44	-182.02	-129.02	-103.25	-39.52	-48.16	-17.78	-6.05
FCF Conversion (FCF/Net Income)	0.00x	0.92x	0.04x	0.81x	0.35x	0.60x	0.59x	1.20x	0.60x	0.48x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-57.1%	-70.44%	-106.12%	-87.62%	-78.03%	-55.76%	-82.4%	-121.65%
Return on Invested Capital (ROIC)	-	-	-69.6%	-	-62.63%	-89.93%	-130.72%	-122.8%	-145.24%	-153.57%
Gross Margin	-	-	100%	-	-	-	-	-	-	-
Net Margin	-	-	-13586.02%	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.04x	0.01x	0.01x	0.02x	0.03x	0.08x
Interest Coverage	-	-	-	-	-144.76x	-130.28x	-486.19x	-561.83x	-79563.54x	-339.16x
FCF Conversion	0.00x	0.92x	0.04x	0.81x	0.35x	0.60x	0.59x	1.20x	0.60x	0.48x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Quantum BioPharma Ltd. (QNTM) grew revenue by 0.0% over the past year. Growth has been modest.

Quantum BioPharma Ltd. (QNTM) reported a net loss of $28.5M for fiscal year 2024.

Dividend & Returns

Quantum BioPharma Ltd. (QNTM) has a return on equity (ROE) of -121.7%. Negative ROE indicates the company is unprofitable.

Quantum BioPharma Ltd. (QNTM) had negative free cash flow of $8.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Quantum BioPharma Ltd. (QNTM) 10-Year Financial Performance & Capital Metrics

QNTM • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

Revenue $0
EBITDA -$16M +26.5%
Net Income -$14M +20.7%
EPS (Diluted) -12.49 +57.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -121.65% -47.6%
ROIC -153.57% -5.7%
Debt/Equity 0.08 +200.7%
Interest Coverage -339.16 +99.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 86.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-180.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM-20.25%

ROCE

10Y Avg-84.15%

5Y Avg-94.21%

3Y Avg-104.09%

Latest-138.22%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.49B	135.33	41.13	24.81%	15.95%	14.25%	4.13%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.97B	51.80	39.24	8.94%	-2.8%	-1.82%	5.76%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	26.94M	7.01	-0.56			-379.78%		0.08
AYTUAytu BioPharma, Inc.	28.02M	2.75	-1.27	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	429.45M	3.52	-6.90	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.50	-42.16	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	17.39B	35.17	-4042.53			-67.02%		0.01

Profit & Loss

	Aug 2015	Aug 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	20.63K	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	2.04M	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	20.63K	0	-1.84M	0	0	0	0	0
Gross Margin %	-	-	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-1%	-	1%	-	-	-	-
Operating Expenses+	32.8K	29.63K	2.82M	18.62M	20.44M	30.69M	33.74M	27.43M	23.79M	16.14M
OpEx % of Revenue	-	-	136.86%	-	-	-	-	-	-	-
Selling, General & Admin	32.8K	29.63K	2.82M	17.49M	20.49M	18.11M	23.37M	15.98M	13.2M	9.31M
SG&A % of Revenue	-	-	136.86%	-	-	-	-	-	-	-
Research & Development	0	0	0	0	0	7.83M	6.33M	6.91M	3.86M	6.08M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	1.13M	-45.53K	4.75M	4.05M	4.54M	6.73M	742.8K
Operating Income+	0	0	-2.8M	0	-22.48M	-30.69M	-33.74M	-27.43M	-23.79M	-16.14M
Operating Margin %	-	-	-135.86%	-	-	-	-	-	-	-
Operating Income Growth %	-	-	-	1%	-	-0.37%	-0.1%	0.19%	0.13%	0.32%
EBITDA+	-32.8K	-29.63K	-2.8M	-16.54M	-20.54M	-26.79M	-29.7M	-22.89M	-21.28M	-15.65M
EBITDA Margin %	-	-	-135.86%	-	-	-	-	-	-	-
EBITDA Growth %	-	0.1%	-93.6%	-4.9%	-0.24%	-0.3%	-0.11%	0.23%	0.07%	0.26%
D&A (Non-Cash Add-back)	0	0	0	134.5K	1.94M	3.9M	4.05M	4.54M	2.51M	490.57K
EBIT	-32.8K	-29.63K	-2.8M	-16.67M	-33.93M	-28.22M	-33.87M	-26.65M	-18.23M	-14.87M
Net Interest Income+	0	0	0	0	-155.32K	-231.89K	-68.11K	318.91K	786.06K	525.31K
Interest Income	0	0	0	0	0	3.69K	1.29K	367.74K	786.36K	572.89K
Interest Expense	0	0	0	0	155.32K	235.58K	69.4K	48.82K	299	47.58K
Other Income/Expense	-32.8K	-29.63K	0	-16.67M	-11.6M	2.24M	-194.3K	725.95K	5.56M	1.22M
Pretax Income+	-32.8K	-29.63K	-2.8M	-16.67M	-34.08M	-28.45M	-33.94M	-26.7M	-18.23M	-14.92M
Pretax Margin %	-	-	-135.86%	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.15%	1.12%	1.04%	0.88%	0.98%	0.95%
Net Income+	-32.8K	-29.63K	-2.8M	-16.67M	-39.13M	-31.8M	-35.29M	-23.61M	-17.9M	-14.2M
Net Margin %	-	-	-135.86%	-	-	-	-	-	-	-
Net Income Growth %	-	0.1%	-93.6%	-4.95%	-1.35%	0.19%	-0.11%	0.33%	0.24%	0.21%
Net Income (Continuing)	-32.8K	-29.63K	-2.8M	-16.67M	-34.08M	-28.45M	-33.94M	-26.7M	-18.23M	-14.92M
Discontinued Operations	0	0	0	0	0	-3.35M	-1.35M	3.1M	0	0
Minority Interest	0	0	0	0	0	0	0	0	-327.5K	-1.04M
EPS (Diluted)+	-0.32	-0.29	-27.75	-183.54	-360.45	-171.62	-65.63	-39.62	-29.39	-12.49
EPS Growth %	-	0.09%	-94.69%	-5.61%	-0.96%	0.52%	0.62%	0.4%	0.26%	0.58%
EPS (Basic)	-0.32	-0.29	-27.75	-183.54	-360.45	-171.62	-65.63	-39.62	-29.39	-12.49
Diluted Shares Outstanding	101K	101K	101K	90.85K	108.56K	185.29K	537.62K	595.88K	609.06K	1.14M
Basic Shares Outstanding	101K	101K	101K	90.85K	108.56K	185.29K	537.62K	595.88K	609.06K	1.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Aug 2015	Aug 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.16K	7.14K	4.28M	16.57M	8.56M	26.87M	45.93M	17.85M	11.09M	12.05M
Cash & Short-Term Investments	0	7.14K	3.77M	15.52M	5.97M	17.52M	35.42M	17M	3.51M	7.2M
Cash Only	0	7.14K	3.77M	15.52M	5.97M	17.52M	35.26M	16.98M	2.76M	6M
Short-Term Investments	0	0	0	0	0	0	158.04K	23.19K	756.1K	1.2M
Accounts Receivable	2.16K	0	234.2K	727.58K	1.56M	161.34K	500.96K	374.38K	7.42M	3.81M
Days Sales Outstanding	-	-	4.14K	-	-	-	-	-	-	-
Inventory	0	0	0	0	709.37K	0	0	0	0	117.24K
Days Inventory Outstanding	-	-	-	-	126.96	-	-	-	-	-
Other Current Assets	0	0	0	0	0	8.61M	8.65M	0	0	861.23K
Total Non-Current Assets+	0	0	6.59M	22.18M	34.66M	15.1M	17.03M	20.56M	6.39M	5.07M
Property, Plant & Equipment	0	0	6.59M	8.91M	8.98M	0	168.31K	260.93K	120.42K	130.38K
Fixed Asset Turnover	-	-	0.00x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	16.82M	13.42M	16.2M	12.04M	5.36M	4.93M
Long-Term Investments	0	0	0	13.26M	8.86M	1.68M	660.23K	827.61K	6.05K	2.22K
Other Non-Current Assets	0	0	0	0	0	0	0	7.43M	907.37K	0
Total Assets+	2.16K	7.14K	10.88M	38.75M	43.22M	41.97M	62.96M	38.41M	17.47M	17.12M
Asset Turnover	-	-	0.00x	-	-	-	-	-	-	-
Asset Growth %	-	2.3%	1523.21%	2.56%	0.12%	-0.03%	0.5%	-0.39%	-0.55%	-0.02%
Total Current Liabilities+	60.53K	61.43K	1.01M	1.28M	6.83M	5.58M	8.7M	7.83M	4.57M	6.68M
Accounts Payable	36.75K	28.31K	1.01M	1.28M	3.36M	2.06M	3M	2.76M	3.24M	3.25M
Days Payables Outstanding	-	-	-	-	601.54	-	-	-	-	-
Short-Term Debt	18.04K	0	0	0	1.44M	384.65K	300.55K	300.55K	300.55K	771.14K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	0	0	0	0	1.99M	1.61M	811.43K	243.59K	31.34K	492K
Current Ratio	0.04x	0.12x	4.26x	12.94x	1.25x	4.82x	5.28x	2.28x	2.43x	1.80x
Quick Ratio	0.04x	0.12x	4.26x	12.94x	1.15x	4.82x	5.28x	2.28x	2.43x	1.79x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	110.33K	79.12K	131.04K	38K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	110.33K	79.12K	131.04K	38K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	60.53K	61.43K	1.01M	1.28M	6.94M	5.66M	8.83M	7.87M	4.57M	6.68M
Total Debt+	18.04K	0	0	0	1.59M	510.61K	555.9K	516.42K	339.2K	824.92K
Net Debt	18.04K	-7.14K	-3.77M	-15.52M	-4.38M	-17.01M	-34.7M	-16.46M	-2.42M	-5.17M
Debt / Equity	-	-	-	-	0.04x	0.01x	0.01x	0.02x	0.03x	0.08x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-144.76x	-130.28x	-486.19x	-561.83x	-79563.54x	-339.16x
Total Equity+	-58.37K	-54.3K	9.87M	37.47M	36.28M	36.31M	54.13M	30.54M	12.91M	10.44M
Equity Growth %	-	0.07%	182.81%	2.8%	-0.03%	0%	0.49%	-0.44%	-0.58%	-0.19%
Book Value per Share	-0.58	-0.54	97.74	412.42	334.18	195.95	100.69	51.26	21.20	9.18
Total Shareholders' Equity	-58.37K	-54.3K	9.87M	37.47M	36.28M	36.31M	54.13M	30.54M	13.24M	11.48M
Common Stock	1.06M	1.07M	10.34M	49.87M	73.74M	103.21M	152.32M	143.41M	137.78M	150.47M
Retained Earnings	-1.26M	-1.3M	-3.35M	-19.46M	-59.07M	-90.87M	-126.15M	-144.16M	-157.91M	-172.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	-84.78K	207.8K	239.61K	652.6K	417.34K	50.8K
Minority Interest	0	0	0	0	0	0	0	0	-327.5K	-1.04M

Cash Flow

	Aug 2015	Aug 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-63	-27.24K	-119.18K	-13.58M	-13.71M	-19.13M	-20.75M	-28.33M	-10.83M	-6.88M
Operating CF Margin %	-	-	-5.78%	-	-	-	-	-	-	-
Operating CF Growth %	-	-428.39%	-3.38%	-112.91%	-0.01%	-0.4%	-0.08%	-0.37%	0.62%	0.36%
Net Income	-32.8K	-29.63K	-2.81M	-16.67M	-34.08M	-28.45M	-33.94M	-26.7M	-18.23M	-14.92M
Depreciation & Amortization	0	0	0	134.13K	1.94M	3.9M	4.05M	4.53M	2.51M	490.57K
Stock-Based Compensation	0	0	2.38M	4.73M	12.08M	8.05M	7.44M	1.53M	3.84M	152.21K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	0	0	-1.52M	5.24M	-3.44M	-1.19M	-575.13K	-576.27K	-2.36M
Working Capital Changes	32.74K	2.39K	305.41K	-242.37K	1.1M	807.14K	2.89M	-7.12M	1.64M	9.76M
Change in Receivables	881	2.19K	-217.72K	-487.95K	-387.84K	435.18K	-106.88K	-7.22M	-728.72K	4.52M
Change in Inventory	0	0	0	0	-721.86K	0	0	0	0	-117.24K
Change in Payables	12.62K	-8.87K	790.97K	318.46K	825.12K	0	0	0	0	0
Cash from Investing+	0	0	-6.09M	-7.34M	-230.89K	6.51M	268.96K	12.12M	-269.58K	-1.5M
Capital Expenditures	0	0	-6.09M	-2.96M	-408.89K	0	-500K	-113.96K	0	0
CapEx % of Revenue	-	-	295.02%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-286.06K	36.62K	0	-250K	0	0
Cash from Financing+	0	34.38K	9.95M	32.95M	4.01M	24.17M	38.21M	-2.07M	-3.13M	11.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	34.38K	-1.01M	-81.68K	622.59K	59.55K	0	0	20.25K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-63	-27.24K	-6.21M	-16.54M	-14.01M	-19.13M	-21.25M	-28.7M	-10.83M	-6.88M
FCF Margin %	-	-	-300.8%	-	-	-	-	-	-	-
FCF Growth %	-	-428.39%	-226.82%	-1.66%	0.15%	-0.37%	-0.11%	-0.35%	0.62%	0.36%
FCF per Share	-0.00	-0.27	-61.44	-182.02	-129.02	-103.25	-39.52	-48.16	-17.78	-6.05
FCF Conversion (FCF/Net Income)	0.00x	0.92x	0.04x	0.81x	0.35x	0.60x	0.59x	1.20x	0.60x	0.48x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-57.1%	-70.44%	-106.12%	-87.62%	-78.03%	-55.76%	-82.4%	-121.65%
Return on Invested Capital (ROIC)	-	-	-69.6%	-	-62.63%	-89.93%	-130.72%	-122.8%	-145.24%	-153.57%
Gross Margin	-	-	100%	-	-	-	-	-	-	-
Net Margin	-	-	-13586.02%	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.04x	0.01x	0.01x	0.02x	0.03x	0.08x
Interest Coverage	-	-	-	-	-144.76x	-130.28x	-486.19x	-561.83x	-79563.54x	-339.16x
FCF Conversion	0.00x	0.92x	0.04x	0.81x	0.35x	0.60x	0.59x	1.20x	0.60x	0.48x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Quantum BioPharma Ltd. (QNTM) grew revenue by 0.0% over the past year. Growth has been modest.

Quantum BioPharma Ltd. (QNTM) reported a net loss of $28.5M for fiscal year 2024.

Dividend & Returns

Quantum BioPharma Ltd. (QNTM) has a return on equity (ROE) of -121.7%. Negative ROE indicates the company is unprofitable.

Quantum BioPharma Ltd. (QNTM) had negative free cash flow of $8.8M in fiscal year 2024, likely due to heavy capital investments.